48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE.

48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE. Based on criteria 1 reflecting only first obtained CC view, degree of BPE is classified as mild; based on criteria 2 reflecting both obtained CC views, degree of BPE is classified as moderate. Histopathologic assessment from subsequent biopsy demonstrated both masses to be invasive ductal carcinoma. 

 


January 27, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), both menstrual status and menstrual cycle time are associated with the degree of early background parenchymal enhancement (BPE) on contrast-enhanced mammography (CEM), which could influence CEM interpretations. 

“Clinical factors, including history of breast cancer or breast cancer treatment, breast density, menstrual status, and time of menstrual cycle, are associated with degree of early BPE on CEM,” wrote corresponding author Yajia Gu from the department of radiology at Fudan University Shanghai Cancer Center in China. “In premenopausal patients, degree of BPE is lowest on days 8–14 of the menstrual cycle.” 

This AJR accepted manuscript included 207 patients (median age, 46 years) who underwent CEM between April 2020 and September 2021. Two radiologists independently assessed BPE degree on CEM (minimal, mild, moderate, or marked) based on two criteria: using the first of four obtained views; using the first two of four obtained views. Reviewing electronic medical records for clinical factors, the radiologist pair reached consensus for breast density via CEM. 

Ultimately, degree of early BPE on CEM was negatively associated with age, history of breast cancer, chemotherapy or radiation therapy, as well as perimenopausal and postmenopausal status. Meanwhile, early BPE degree on this modality was positively associated with dense breasts and premenopausal status with irregular cycles.   

Acknowledging their retrospective study’s small sample size, given the potential impact of BPE on diagnostic performance, “the findings have implications for CEM scheduling and interpretation,” the authors of this AJR accepted manuscript added

For more information: www.arrs.org 

Related Breast Imaging Content: 

Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis 

Today's Mammography Advancements  

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings  

AI DBT Impact on Mammography Post-breast Therapy  

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI  

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs  

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography 

Study Finds Racial Disparities in Access to New Mammography Technology 

American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation 


Related Content

News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Breast Imaging

Oct. 28, 2025 — QT Imaging Holdings, Inc., a medical device company focused on radiation-free imaging technology, has ...

Time October 28, 2025
arrow
Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Breast Imaging

Oct. 15, 2025 — Leading into Breast Cancer Awareness Month, Fujifilm Healthcare Americas Corp. and Beekley Medical ...

Time October 15, 2025
arrow
News | Breast Imaging

Oct. 3, 2025 — Gnosis for Her, a mobile breast health initiative redefining comfort and access in women's breast imaging ...

Time October 06, 2025
arrow
News | Mammography | Mayo Clinic

Early detection is key to breast cancer survival. But nearly half of all women in the U.S. have dense breast tissue ...

Time October 03, 2025
arrow
News | Mammography

Sept. 26, 2025 — Data from two groundbreaking studies evaluating the performance of Hologic’s artificial intelligence ...

Time October 02, 2025
arrow
News | Prostate Cancer

Sept. 30, 2025 – EDAP TMS's non-invasive, nonsurgical treatment option, Focal One Robotic HIFU, was featured on national ...

Time September 30, 2025
arrow
Subscribe Now